Skip to main content

Table 3 FNA performance per cytology group

From: The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes

Performance on AUS/FLUS (n = 12)
Genetic alteration Histology malignant (n = 1) Histology benign (n = 11)
Positive 0 1
Negative 1 10
  1. Sensitivity, 0 % (0–98); Specificity, 91 % (59–100); PPV, 16 % (4–45); NPV, 93 % (87–97), prevalence of malignant lesions, 8 %. Estimated performance when malignancy is prevalent at 24 %: PPV, 40 % (12–74); NPV, 81 % (66–90)